COSCIENS Biopharma Inc. (CSCIF) stock
CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
$6.49+0.00 (0.00%)
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
COSCIENS Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
COSCIENS Biopharma's R&D Expenses for the twelve months ending Mar 31, 2026 was $1.99M, down 74.3% year over year. For fiscal 2025 it was $2.95M, down 64.5% from the year before. Over ten years it grew -16.2% a year on average. The highest annual figure on record is $17.23M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.95M | -64.5% |
| FY2024 | Dec 31, 2024 | $8.30M | +307.1% |
| FY2023 | Dec 31, 2023 | $2.04M | +48.8% |
| FY2022 | Dec 31, 2022 | $1.37M | -79.1% |
| FY2021 | Dec 31, 2021 | $6.57M | +336.5% |
| FY2020 | Dec 31, 2020 | $1.51M | -18.0% |
| FY2019 | Dec 31, 2019 | $1.84M | -37.3% |
| FY2018 | Dec 31, 2018 | $2.93M | -72.6% |
| FY2017 | Dec 31, 2017 | $10.70M | -35.1% |
| FY2016 | Dec 31, 2016 | $16.50M | -4.3% |
| FY2015 | Dec 31, 2015 | $17.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $176.00K | -64.6% |
| Q4 FY2025 | Dec 31, 2025 | $599.00K | -79.4% |
| Q3 FY2025 | Sep 30, 2025 | $527.00K | -81.2% |
| Q2 FY2025 | Jun 30, 2025 | $690.00K | -54.9% |
| Q1 FY2025 | Mar 31, 2025 | $497.00K | -53.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.91M | +495.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.80M | +542.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.53M | +121.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.06M | -73.5% |
| Q4 FY2023 | Dec 31, 2023 | $489.00K | -88.9% |
| Q3 FY2023 | Sep 30, 2023 | $436.00K | -86.8% |
| Q2 FY2023 | Jun 30, 2023 | $691.00K | -71.2% |
| Q1 FY2023 | Mar 31, 2023 | $4.01M | +67.9% |
| Q4 FY2022 | Dec 31, 2022 | $4.43M | +137.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.29M | +121.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.40M | +35.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.39M | +63.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.86M | +197.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.49M | +299.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.77M | +835.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.46M | +357.1% |
| Q4 FY2020 | Dec 31, 2020 | $626.00K | +138.0% |
| Q3 FY2020 | Sep 30, 2020 | $372.00K | -21.7% |
| Q2 FY2020 | Jun 30, 2020 | $189.00K | -66.9% |
| Q1 FY2020 | Mar 31, 2020 | $319.00K | -39.6% |
| Q4 FY2019 | Dec 31, 2019 | $263.00K | -65.7% |
| Q3 FY2019 | Sep 30, 2019 | $475.00K | +32.7% |
| Q2 FY2019 | Jun 30, 2019 | $571.00K | -41.4% |
| Q1 FY2019 | Mar 31, 2019 | $528.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $767.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $358.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $974.00K | – |
See a number that looks wrong?